Funding for Tobacco Use and HIV in Low and Middle Income Countries (LMICs)

February 8, 2017
Mark Parascandola

This webinar provides key information about the R01 and R21 funding opportunity announcements, Tobacco Use and HIV in Low and Middle Income Countries. The announcements have been reissued as PAR-18-023 (R01 Clinical Trial Optional) and PAR-18-022 (R21 Clinical Trial Optional).

Epidemiologist Dr. Mark Parascandola of the National Cancer Institute (NCI) Tobacco Control Research Branch provides an overview of this funding opportunity, which aims to develop and evaluate tobacco cessation interventions tailored to HIV-positive populations - including those with co-morbidities such as tuberculosis (TB) - in low-resource settings in low- and middle-income countries.

Last Updated
September 24, 2020